# Axel Haupt

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/axel-haupt/

## Facts

| Field | Value |
| --- | --- |
| Citations | 11,031 |
| Field | Diabetes Treatment and Management |
| h-index | 47 |
| i10-index | 82 |
| Last Known Institution | Accadis Hochschule Bad Homburg |
| OpenAlex ID | https://openalex.org/A5040811419 |
| ORCID iD | 0000-0003-4502-0470 |
| Works | 186 |

## Researcher papers

- [Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial](https://scholariq.org/papers/triple-hormone-receptor-agonist-retatrutide-for-obesity-a-phase-2-trial/)
- [Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis](https://scholariq.org/papers/tirzepatide-for-metabolic-dysfunction-associated-steatohepatitis-with-liver/)
- [LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept](https://scholariq.org/papers/ly3298176-a-novel-dual-gip-and-glp-1-receptor-agonist-for-the-treatment-of-type/)
- [Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial](https://scholariq.org/papers/efficacy-and-safety-of-ly3298176-a-novel-dual-gip-and-glp-1-receptor-agonist-in/)
- [Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity](https://scholariq.org/papers/daily-oral-glp-1-receptor-agonist-orforglipron-for-adults-with-obesity/)
- [Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA](https://scholariq.org/papers/retatrutide-a-gip-glp-1-and-glucagon-receptor-agonist-for-people-with-type-2/)
- [Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries](https://scholariq.org/papers/management-of-dyslipidaemia-in-patients-with-coronary-heart-disease-results-from/)
- [Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes](https://scholariq.org/papers/effects-of-novel-dual-gip-and-glp-1-receptor-agonist-tirzepatide-on-biomarkers/)
- [Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes](https://scholariq.org/papers/dual-gip-and-glp-1-receptor-agonist-tirzepatide-improves-beta-cell-function-and/)
- [LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept](https://scholariq.org/papers/ly3437943-a-novel-triple-glucagon-gip-and-glp-1-receptor-agonist-for-glycemic/)
- [Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial](https://scholariq.org/papers/effects-of-tirzepatide-versus-insulin-glargine-on-kidney-outcomes-in-type-2/)
- [Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1–5 Clinical Trials](https://scholariq.org/papers/tirzepatide-associated-with-reduced-albuminuria-in-participants-with-type-2/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)
- [Diet and metabolism studies](https://scholariq.org/topics/diet-and-metabolism-studies/)

## Researcher university

- [Accadis Hochschule Bad Homburg](https://scholariq.org/institutions/accadis-hochschule-bad-homburg/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.